Dr. Kavalerchik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Hampshire St
Cambridge, MA 02139Phone+1 617-315-2255
Summary
- Dr. Edward Kavalerchik is an oncologist in California. He received his medical degree from Stony Brook University School of Medicine and has been in practice or drug and cell clinical therapy development 17 years. He specializes in General Oncology including a broad range of solid malignancies as well as Hematologic Oncology including blood and marrow transplantation. Acute Leukemia, Myelodysplasia, Myelofibrosis, Multiple myeloma, Amyloidosis, and Lymphoma.
Education & Training
Scripps Translational Science Institute, TSRICandidate for MS, 2009 - 2011
University of California (San Diego) Medical CenterFellowship, California Institute For Regenerative Medicine, 2007 - 2009- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2002 - 2005
Stony Brook University Health Sciences Center School of MedicineClass of 2002- Massachusetts Institute of TechnologyBS, Biology, Minors in Chemistry and Political Science, 1992 - 1996
Certifications & Licensure
CA State Medical License 2004 - 2026
Clinical Trials
- A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Start of enrollment: 2016 Sep 01
- A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer Start of enrollment: 2017 Mar 08
- SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers Start of enrollment: 2017 Jun 14
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsSerum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Ravi Vij, Michael Wang, Sundar Jagannath, Ruben Niesvizky, Andrzej Jakubowiak
Leukemia & Lymphoma. 2015-02-20 - 108 citationsPhase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myelomaMichael Wang, Thomas Martin, William I. Bensinger, Melissa Alsina, David S. Siegel
Blood. 2013-10-31 - 103 citationsChronic Myeloid Leukemia Stem CellsEdward Kavalerchik, Daniel Goff, Catriona Jamieson
Journal of Clinical Oncology. 2008-06-10
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
